USFDA issues three observations to Biocon’s Telangana manufacturing plant

22 Jul 2022 Evaluate

The US Food and Drug Administration (USFDA) have issued three observations after inspecting Biocon’s Telangana-based manufacturing plant. USFDA concluded a pre-approval inspection for Site 3 located at Hyderabad on July 20, 2022. Three observations were cited at the end of the inspection, which the company will be addressing within the stipulated time. The company stands committed to quality, safety and efficacy of its products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

366.40 -6.25 (-1.68%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×